As I See It: Pharma's public image

Share this article:
Paul D. Thacker
Paul D. Thacker

In recent years, pharma executives have begun a bit of hand wringing over the public perception that their industry is corrupt.

Two years ago, Deirdre Connelly, President, North America Pharmaceuticals, GlaxoSmithKline, told a crowd: “I believe that, in some ways our industry lost its way, and failed to fully appreciate the evolving expectations of our stakeholders.”

Former Pfizer president John LaMattina has even written a new book asking if the industry can “restore its broken image.”

Let's all agree on one thing. It will take a lot of work. The image of pharma as corrupt is not a ­problem of perception. It's one of fact.

In early December, German television ran a documentary about a secret program in the ­former East Germany, which invited Western drug companies to ­experiment on its citizens. In exchange, companies paid the cash strapped nation millions.

Creating a program in the nation that witnessed the Nuremberg trials, whose behavior led to founding of basic ethics in medical research—is there anything more ironic? More outright disgusting?

It's easy to predict the response of corporate attorneys: “This program took place years in the past, before recent changes, and does not reflect current practices.”

Sure. But we cannot forget history. Not because people cannot change. Not because Pharma is not trying to become more ethical. But because the best predictors of future behavior are past actions.

Thacker, a former Congressional investigator, is a consultant to nonprofits and foundations and a Lab Fellow at the Edmond J. Safra Center for Ethics at Harvard University
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications